CAR T-cell therapy: which product for which patient?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer.International journal of molecular sciences · 2026
   Article
2. Scalable manufacturing of gene-modified human mesenchymal stromal cells with microcarriers in spinner flasks.Applied microbiology and biotechnology · 2023
   Article
3. Bubble-Based Drug Delivery Systems: Next-Generation Diagnosis to Therapy.Journal of functional biomaterials · 2023
   Review
4. Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications.Current oncology (Toronto, Ont.) · 2023
   Review

Corrections and comments

• Comment on
  Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.2022

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as